Equip F vet.
Active substance
ATC code
Species
Horses from 5 months of age
Indications
For the active immunisation of horses of 5 months of age or older against Equine Influenza of H7N7 and H3N8 types (European or American strains, including Florida sublineage Clade 1 and Clade 2 isolates) to reduce clinical signs and virus excretion after infection.
Duration of immunity is at least 15 months.
Onset of immunity is within 2 weeks of completion of the primary course.
Dose to be administered and administration route
Dose: 2 ml
Administration: Equip F should be shaken thoroughly before use, and administered by deep intramuscular injection.
Vaccination Regime: For protection against equine influenza, Equip F should be used as follows:
|
Primary Course |
First dose |
EQUIP F 6 week interval |
|
Second dose |
EQUIP F 5 month interval |
|
|
Boosters |
1st booster |
EQUIP F 12-15 month interval |
|
2nd and subsequent boosters |
EQUIP F 12-15 month intervals |
|
Note: The routine practice of administering booster doses annually may remain the most convenient, even though protection against equine influenza has been demonstrated by challenge studies 15 months following the third vaccination (first booster dose). No field challenge studies have been carried out prior to the third vaccination; instead efficacy was evaluated by serology which showed titres equivalent to those found in horses protected against challenge at 15 months.
It is recommended that a single booster dose should only be administered to horses that have already received a full primary course using vaccines that contain the same types of equine influenza virus included in this vaccine. A full primary course may be considered necessary in horses that have not been suitably primed.
Adverse reactions
Rarely (<1 in 1000), animals may exhibit a reaction to vaccination. This may be manifest by stiffness, a mild, transient rise in temperature, typically 9-12 hours post vaccination, or a small soft, non-painful local swelling (10-20 mm in diameter) at the injection site. These conditions normally resolve by the day following vaccination.
Injection site pain, anorexia and lethargy have been reported in very rare cases (<1 in10, 000).
Occasional hypersensitivity reactions may occur. In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.
